Risk assessment in pulmonary arterial hypertension
- PMID: 29599117
- DOI: 10.1183/13993003.02606-2017
Risk assessment in pulmonary arterial hypertension
Conflict of interest statement
Conflict of interest: M.M. Hoeper reports receiving personal fees from Actelion, Bayer, GSK, Pfizer, Gilead and Merck, during the conduct of the study. Conflict of interest: D. Pittrow reports receiving personal fees from Actelion, Aspen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Pfizer and AstraZeneca, outside the submitted work. Conflict of interest: C. Opitz reports receving personal fees from Actelion, Bayer, GSK, Pfizer and Novartis, during the conduct of the study. Conflict of interest: J.S.R. Gibbs reports receiving personal fees from Actelion, Bayer, GSK, Pfizer, MSD, Bellerophon and Arena, during the conduct of the study. Conflict of interest: S. Rosenkranz reports receving grants and personal fees from Actelion, Bayer, Pfizer, Novartis and United Therapeutics, and personal fees from GSK, Gilead and MSD, during the conduct of the study. Conflict of interest: E. Grünig reports receiving personal fees from Actelion, Bayer, GSK, Pfizer, United Therapeutics and MSD, outside the submitted work. Conflict of interest: K.M. Olsson reports receiving personal fees from Actelion, Bayer, GSK, Pfizer and United Therapeutics, during the conduct of the study. Conflict of interest: D. Huscher reports receiving personal fees from Actelion outside the submitted work.
Comment in
-
Risk assessment in pulmonary arterial hypertension.Eur Respir J. 2018 Mar 29;51(3):1800279. doi: 10.1183/13993003.00279-2018. Print 2018 Mar. Eur Respir J. 2018. PMID: 29599118 No abstract available.
Comment on
-
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.Eur Respir J. 2017 Aug 3;50(2):1700740. doi: 10.1183/13993003.00740-2017. Print 2017 Aug. Eur Respir J. 2017. PMID: 28775047
-
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.Eur Respir J. 2017 Aug 3;50(2):1700889. doi: 10.1183/13993003.00889-2017. Print 2017 Aug. Eur Respir J. 2017. PMID: 28775050
Similar articles
-
Validation of a risk assessment instrument for pulmonary arterial hypertension.Eur Heart J. 2018 Dec 14;39(47):4182-4185. doi: 10.1093/eurheartj/ehx301. Eur Heart J. 2018. PMID: 28637288 No abstract available.
-
Risk assessment in pulmonary arterial hypertension.Eur Respir J. 2018 Mar 29;51(3):1800279. doi: 10.1183/13993003.00279-2018. Print 2018 Mar. Eur Respir J. 2018. PMID: 29599118 No abstract available.
-
[Echocardiography and other imaging modalities in pulmonary arterial hypertension].Anadolu Kardiyol Derg. 2010 Aug;10 Suppl 1:27-35. doi: 10.5152/akd.2010.116. Anadolu Kardiyol Derg. 2010. PMID: 20819764 Review. Turkish.
-
Prognostic Stratification and Treatment for Pulmonary Arterial Hypertension. Gaps and Promising Remedies.Arch Bronconeumol. 2023 Oct;59(10):617-618. doi: 10.1016/j.arbres.2023.04.003. Epub 2023 Apr 20. Arch Bronconeumol. 2023. PMID: 37147267 English, Spanish. No abstract available.
-
Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis.J Am Soc Echocardiogr. 2013 Jan;26(1):1-14. doi: 10.1016/j.echo.2012.10.009. Epub 2012 Nov 8. J Am Soc Echocardiogr. 2013. PMID: 23140849 Review.
Cited by
-
What's new in pulmonary hypertension clinical research: lessons from the best abstracts at the 2020 American Thoracic Society International Conference.Pulm Circ. 2021 Aug 25;11(3):20458940211040713. doi: 10.1177/20458940211040713. eCollection 2021 Jul-Sep. Pulm Circ. 2021. PMID: 34471517 Free PMC article.
-
Risk assessment in precapillary pulmonary hypertension: a comparative analysis.Respir Res. 2021 Jan 21;22(1):28. doi: 10.1186/s12931-021-01624-z. Respir Res. 2021. PMID: 33478493 Free PMC article.
-
The haemodynamic assessment of patients with pulmonary arterial hypertension.Glob Cardiol Sci Pract. 2020 Apr 30;2020(1):e202004. doi: 10.21542/gcsp.2020.4. Glob Cardiol Sci Pract. 2020. PMID: 33150149 Free PMC article. Review. No abstract available.
-
ER-stress-induced secretion of circulating glucose-regulated protein 78kDa (GRP78) ameliorates pulmonary artery smooth muscle cell remodelling.Cell Stress Chaperones. 2022 Sep;27(5):561-572. doi: 10.1007/s12192-022-01292-y. Epub 2022 Aug 27. Cell Stress Chaperones. 2022. PMID: 36029373 Free PMC article.
-
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.Eur Respir J. 2022 Jul 7;60(1):2102311. doi: 10.1183/13993003.02311-2021. Print 2022 Jul. Eur Respir J. 2022. PMID: 34737226 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical